192 related articles for article (PubMed ID: 37922690)
1. Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF
Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
[TBL] [Abstract][Full Text] [Related]
2. Vemurafenib in non-small-cell lung cancer patients with BRAF
Mazieres J; Cropet C; Montané L; Barlesi F; Souquet PJ; Quantin X; Dubos-Arvis C; Otto J; Favier L; Avrillon V; Cadranel J; Moro-Sibilot D; Monnet I; Westeel V; Le Treut J; Brain E; Trédaniel J; Jaffro M; Collot S; Ferretti GR; Tiffon C; Mahier-Ait Oukhatar C; Blay JY
Ann Oncol; 2020 Feb; 31(2):289-294. PubMed ID: 31959346
[TBL] [Abstract][Full Text] [Related]
3. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.
Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM
JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
Hyman DM; Puzanov I; Subbiah V; Faris JE; Chau I; Blay JY; Wolf J; Raje NS; Diamond EL; Hollebecque A; Gervais R; Elez-Fernandez ME; Italiano A; Hofheinz RD; Hidalgo M; Chan E; Schuler M; Lasserre SF; Makrutzki M; Sirzen F; Veronese ML; Tabernero J; Baselga J
N Engl J Med; 2015 Aug; 373(8):726-36. PubMed ID: 26287849
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
6. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
7. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF
Blank CU; Larkin J; Arance AM; Hauschild A; Queirolo P; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Garbe C; Chiarion Sileni V; Mandalà M; Gogas H; Espinosa E; Hospers GAP; Miller WH; Robson S; Makrutzki M; Antic V; Brown MP
Eur J Cancer; 2017 Jul; 79():176-184. PubMed ID: 28501764
[TBL] [Abstract][Full Text] [Related]
8. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R; Queirolo P; Abajo Guijarro AM; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
Lancet Oncol; 2022 Sep; 23(9):1145-1155. PubMed ID: 35940183
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
McArthur GA; Chapman PB; Robert C; Larkin J; Haanen JB; Dummer R; Ribas A; Hogg D; Hamid O; Ascierto PA; Garbe C; Testori A; Maio M; Lorigan P; Lebbé C; Jouary T; Schadendorf D; O'Day SJ; Kirkwood JM; Eggermont AM; Dréno B; Sosman JA; Flaherty KT; Yin M; Caro I; Cheng S; Trunzer K; Hauschild A
Lancet Oncol; 2014 Mar; 15(3):323-32. PubMed ID: 24508103
[TBL] [Abstract][Full Text] [Related]
11. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
Sosman JA; Kim KB; Schuchter L; Gonzalez R; Pavlick AC; Weber JS; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Hersey P; Kefford R; Lawrence D; Puzanov I; Lewis KD; Amaravadi RK; Chmielowski B; Lawrence HJ; Shyr Y; Ye F; Li J; Nolop KB; Lee RJ; Joe AK; Ribas A
N Engl J Med; 2012 Feb; 366(8):707-14. PubMed ID: 22356324
[TBL] [Abstract][Full Text] [Related]
12. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
13. Safety of vemurafenib in patients with BRAF
Arance AM; Berrocal A; Lopez-Martin JA; de la Cruz-Merino L; Soriano V; Martín Algarra S; Alonso L; Cerezuela P; La Orden B; Espinosa E
Clin Transl Oncol; 2016 Nov; 18(11):1147-1157. PubMed ID: 26983408
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
[TBL] [Abstract][Full Text] [Related]
15. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
16. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
17. BRAF Inhibition in
Kaley T; Touat M; Subbiah V; Hollebecque A; Rodon J; Lockhart AC; Keedy V; Bielle F; Hofheinz RD; Joly F; Blay JY; Chau I; Puzanov I; Raje NS; Wolf J; DeAngelis LM; Makrutzki M; Riehl T; Pitcher B; Baselga J; Hyman DM
J Clin Oncol; 2018 Dec; 36(35):3477-3484. PubMed ID: 30351999
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant vemurafenib in resected, BRAF
Maio M; Lewis K; Demidov L; Mandalà M; Bondarenko I; Ascierto PA; Herbert C; Mackiewicz A; Rutkowski P; Guminski A; Goodman GR; Simmons B; Ye C; Yan Y; Schadendorf D;
Lancet Oncol; 2018 Apr; 19(4):510-520. PubMed ID: 29477665
[TBL] [Abstract][Full Text] [Related]
19. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
20. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
